http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 27 May 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Satellos+Bioscience+Inc.++For%3A+May+27/26553329.html si-local-file:///var/storage/secattach/20260527/26553329.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Satellos+Bioscience+Inc.++For%3A+May+27/26553329.html Wed, 27 May 2026 07:00:00 -0400 MSLE O.03233402 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Satellos+Bioscience+Inc.++For%3A+May+27/26553329.html si-local-file:///var/storage/secattach/20260527/26553329.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Satellos+Bioscience+Inc.++For%3A+May+27/26553329.html Wed, 27 May 2026 07:00:00 -0400 MSLE O.03233402 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Satellos+Bioscience+Inc.++For%3A+May+19/26525122.html si-local-file:///var/storage/secattach/20260520/26525122.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Satellos+Bioscience+Inc.++For%3A+May+19/26525122.html Wed, 20 May 2026 08:00:00 -0400 MSLE O.03233402 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Satellos+Bioscience+Inc.++For%3A+May+19/26525122.html si-local-file:///var/storage/secattach/20260520/26525122.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Satellos+Bioscience+Inc.++For%3A+May+19/26525122.html Wed, 20 May 2026 08:00:00 -0400 MSLE O.03233402 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Satellos+Bioscience+Inc.+++++++++++++++Filed+by%3A+Bloom+Brian+Matthew/26504098.html si-local-file:///var/storage/secattach/20260515/26504098.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Satellos+Bioscience+Inc.+++++++++++++++Filed+by%3A+Bloom+Brian+Matthew/26504098.html Fri, 15 May 2026 15:05:00 -0400 MSLE O.03233402 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Satellos+Bioscience+Inc.+++++++++++++++Filed+by%3A+Bloom+Brian+Matthew/26504098.html si-local-file:///var/storage/secattach/20260515/26504098.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Satellos+Bioscience+Inc.+++++++++++++++Filed+by%3A+Bloom+Brian+Matthew/26504098.html Fri, 15 May 2026 15:05:00 -0400 MSLE O.03233402 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Satellos+Bioscience+Inc.++For%3A+Mar+31/26499202.html si-local-file:///var/storage/secattach/20260515/26499202.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Satellos+Bioscience+Inc.++For%3A+Mar+31/26499202.html Fri, 15 May 2026 07:01:00 -0400 MSLE O.03233402 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Satellos+Bioscience+Inc.++For%3A+Mar+31/26499202.html si-local-file:///var/storage/secattach/20260515/26499202.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Satellos+Bioscience+Inc.++For%3A+Mar+31/26499202.html Fri, 15 May 2026 07:01:00 -0400 MSLE O.03233402 http://www.streetinsider.com/Press+Releases/Satellos+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Company+Progress/26499132.html <ul type="disc"><li><em>Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026</em></li><li><em>BASECAMP remains on track to complete enrollment in Q3 2026</em></li><li><em>The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years.</em></li><li><em>Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027</em></li></ul> <p align="justify">TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- <strong>Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) </strong>(“<strong>Satellos</strong>” or the “<strong>Company</strong>”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced financial results and corporate highlights for the first quarter ended March 31, 2026.</p> http://www.streetinsider.com/Press+Releases/Satellos+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Company+Progress/26499132.html Fri, 15 May 2026 07:00:00 -0400 MSCL MSLE O.03233402 http://www.streetinsider.com/Press+Releases/Satellos+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Company+Progress/26499132.html <ul type="disc"><li><em>Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026</em></li><li><em>BASECAMP remains on track to complete enrollment in Q3 2026</em></li><li><em>The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years.</em></li><li><em>Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027</em></li></ul> <p align="justify">TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- <strong>Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) </strong>(“<strong>Satellos</strong>” or the “<strong>Company</strong>”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced financial results and corporate highlights for the first quarter ended March 31, 2026.</p> http://www.streetinsider.com/Press+Releases/Satellos+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Company+Progress/26499132.html Fri, 15 May 2026 07:00:00 -0400 MSCL MSLE O.03233402 http://www.streetinsider.com/Press+Releases/Satellos+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Company+Progress/26499132.html <ul type="disc"><li><em>Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026</em></li><li><em>BASECAMP remains on track to complete enrollment in Q3 2026</em></li><li><em>The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years.</em></li><li><em>Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027</em></li></ul> <p align="justify">TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- <strong>Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) </strong>(“<strong>Satellos</strong>” or the “<strong>Company</strong>”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced financial results and corporate highlights for the first quarter ended March 31, 2026.</p> http://www.streetinsider.com/Press+Releases/Satellos+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Company+Progress/26499132.html Fri, 15 May 2026 07:00:00 -0400 MSCL MSLE O.03233402 http://www.streetinsider.com/Globe+Newswire/Satellos+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Company+Progress/26499132.html <ul type="disc"><li><em>Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026</em></li><li><em>BASECAMP remains on track to complete enrollment in Q3 2026</em></li><li><em>The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years.</em></li><li><em>Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027</em></li></ul> <p align="justify">TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- <strong>Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) </strong>(“<strong>Satellos</strong>” or the “<strong>Company</strong>”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced financial results and corporate highlights for the first quarter ended March 31, 2026.</p> http://www.streetinsider.com/Globe+Newswire/Satellos+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Company+Progress/26499132.html Fri, 15 May 2026 07:00:00 -0400 MSCL MSLE O.03233402 http://www.streetinsider.com/Globe+Newswire/Satellos+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Company+Progress/26499132.html <ul type="disc"><li><em>Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026</em></li><li><em>BASECAMP remains on track to complete enrollment in Q3 2026</em></li><li><em>The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years.</em></li><li><em>Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027</em></li></ul> <p align="justify">TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- <strong>Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) </strong>(“<strong>Satellos</strong>” or the “<strong>Company</strong>”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced financial results and corporate highlights for the first quarter ended March 31, 2026.</p> http://www.streetinsider.com/Globe+Newswire/Satellos+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Company+Progress/26499132.html Fri, 15 May 2026 07:00:00 -0400 MSCL MSLE O.03233402 http://www.streetinsider.com/Globe+Newswire/Satellos+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Company+Progress/26499132.html <ul type="disc"><li><em>Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026</em></li><li><em>BASECAMP remains on track to complete enrollment in Q3 2026</em></li><li><em>The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years.</em></li><li><em>Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027</em></li></ul> <p align="justify">TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- <strong>Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) </strong>(“<strong>Satellos</strong>” or the “<strong>Company</strong>”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced financial results and corporate highlights for the first quarter ended March 31, 2026.</p> http://www.streetinsider.com/Globe+Newswire/Satellos+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Company+Progress/26499132.html Fri, 15 May 2026 07:00:00 -0400 MSCL MSLE O.03233402 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Satellos+Bioscience+Inc.+++++++++++++++Filed+by%3A+Qiming+U.S.+Healthcare+Fund+III%2C+L.P./26478371.html si-local-file:///var/storage/secattach/20260512/26478371.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Satellos+Bioscience+Inc.+++++++++++++++Filed+by%3A+Qiming+U.S.+Healthcare+Fund+III%2C+L.P./26478371.html Tue, 12 May 2026 16:24:00 -0400 MSCLF MSLE O.03233402 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Satellos+Bioscience+Inc.+++++++++++++++Filed+by%3A+Qiming+U.S.+Healthcare+Fund+III%2C+L.P./26478371.html si-local-file:///var/storage/secattach/20260512/26478371.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Satellos+Bioscience+Inc.+++++++++++++++Filed+by%3A+Qiming+U.S.+Healthcare+Fund+III%2C+L.P./26478371.html Tue, 12 May 2026 16:24:00 -0400 MSCLF MSLE O.03233402 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Satellos+Bioscience+Inc.+++++++++++++++Filed+by%3A+Qiming+U.S.+Healthcare+Fund+III%2C+L.P./26478371.html si-local-file:///var/storage/secattach/20260512/26478371.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Satellos+Bioscience+Inc.+++++++++++++++Filed+by%3A+Qiming+U.S.+Healthcare+Fund+III%2C+L.P./26478371.html Tue, 12 May 2026 16:24:00 -0400 MSCLF MSLE O.03233402 http://www.streetinsider.com/New+Coverage/Guggenheim+Starts+Satellos+Bioscience+Inc.+%28MSLE%29+at+Buy/26377597.html <p>Guggenheim analyst Debjit Chattopadhyay initiates coverage on Satellos Bioscience Inc. (NASDAQ: MSLE) with a Buy rating and a price target of $23.00.</p><p>For an analyst ratings summary and ratings history on Satellos Bioscience Inc. <a href="http://www.streetinsider.com/rating_history.php?q=MSLE">click here</a>. For more ratings news on Satellos Bioscience Inc. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=MSLE&amp;type=analyst">click here</a>.</p><p>Shares of Satellos Bioscience Inc. closed at $7.16 yesterday.</p> http://www.streetinsider.com/New+Coverage/Guggenheim+Starts+Satellos+Bioscience+Inc.+%28MSLE%29+at+Buy/26377597.html Tue, 28 Apr 2026 06:09:58 -0400 MSLE http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Satellos+Bioscience+Inc.++For%3A+Apr+09/26291944.html si-local-file:///var/storage/secattach/20260409/26291944.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Satellos+Bioscience+Inc.++For%3A+Apr+09/26291944.html Thu, 09 Apr 2026 07:00:00 -0400 MSCLF MSLE O.03233402 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Satellos+Bioscience+Inc.++For%3A+Apr+09/26291944.html si-local-file:///var/storage/secattach/20260409/26291944.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Satellos+Bioscience+Inc.++For%3A+Apr+09/26291944.html Thu, 09 Apr 2026 07:00:00 -0400 MSCLF MSLE O.03233402 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Satellos+Bioscience+Inc.++For%3A+Apr+09/26291944.html si-local-file:///var/storage/secattach/20260409/26291944.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Satellos+Bioscience+Inc.++For%3A+Apr+09/26291944.html Thu, 09 Apr 2026 07:00:00 -0400 MSCLF MSLE O.03233402 http://www.streetinsider.com/Press+Releases/Satellos+to+Present+at+the+Bloom+Burton+%26amp%3B+Co.+Healthcare+Investor+Conference/26291925.html <p align="justify">TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- <strong>Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) </strong>(“ <strong>Satellos</strong> ” or the “ <strong>Company</strong> ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton &amp; Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.</p> <p align="justify">Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference.</p> <p align="justify"><strong>2026 Bloom Burton &amp; Co. Healthcare http://www.streetinsider.com/Press+Releases/Satellos+to+Present+at+the+Bloom+Burton+%26amp%3B+Co.+Healthcare+Investor+Conference/26291925.html Thu, 09 Apr 2026 07:00:00 -0400 A.50208689 MSCL MSLE O.03233402 O.22256430 http://www.streetinsider.com/Press+Releases/Satellos+to+Present+at+the+Bloom+Burton+%26amp%3B+Co.+Healthcare+Investor+Conference/26291925.html <p align="justify">TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- <strong>Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) </strong>(“ <strong>Satellos</strong> ” or the “ <strong>Company</strong> ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton &amp; Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.</p> <p align="justify">Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference.</p> <p align="justify"><strong>2026 Bloom Burton &amp; Co. Healthcare http://www.streetinsider.com/Press+Releases/Satellos+to+Present+at+the+Bloom+Burton+%26amp%3B+Co.+Healthcare+Investor+Conference/26291925.html Thu, 09 Apr 2026 07:00:00 -0400 A.50208689 MSCL MSLE O.03233402 O.22256430 http://www.streetinsider.com/Press+Releases/Satellos+to+Present+at+the+Bloom+Burton+%26amp%3B+Co.+Healthcare+Investor+Conference/26291925.html <p align="justify">TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- <strong>Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) </strong>(“ <strong>Satellos</strong> ” or the “ <strong>Company</strong> ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton &amp; Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.</p> <p align="justify">Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference.</p> <p align="justify"><strong>2026 Bloom Burton &amp; Co. Healthcare http://www.streetinsider.com/Press+Releases/Satellos+to+Present+at+the+Bloom+Burton+%26amp%3B+Co.+Healthcare+Investor+Conference/26291925.html Thu, 09 Apr 2026 07:00:00 -0400 A.50208689 MSCL MSLE O.03233402 O.22256430 http://www.streetinsider.com/Press+Releases/Satellos+to+Present+at+the+Bloom+Burton+%26amp%3B+Co.+Healthcare+Investor+Conference/26291925.html <p align="justify">TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- <strong>Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) </strong>(“ <strong>Satellos</strong> ” or the “ <strong>Company</strong> ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton &amp; Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.</p> <p align="justify">Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference.</p> <p align="justify"><strong>2026 Bloom Burton &amp; Co. Healthcare http://www.streetinsider.com/Press+Releases/Satellos+to+Present+at+the+Bloom+Burton+%26amp%3B+Co.+Healthcare+Investor+Conference/26291925.html Thu, 09 Apr 2026 07:00:00 -0400 A.50208689 MSCL MSLE O.03233402 O.22256430